Full Text View
Tabular View
No Study Results Posted
Related Studies
Nippon Ultra-Rapid Insulin and Diabetic Complication Evaluation-Study (NICE-Study)
This study has been completed.
Study NCT00575172   Information provided by Osaka Saiseikai Nakatsu Hospital
First Received: December 17, 2007   Last Updated: January 7, 2008   History of Changes

December 17, 2007
January 7, 2008
March 2003
 
Cardiovascular events 1)Sudden death 2)New development or recurrence of apoplexy or TIA 3)New development or recurrence of AMI or and angina pectoris 4)Newly developed ASO, amputation of leg due to ASO [ Time Frame: five years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00575172 on ClinicalTrials.gov Archive Site
1)Total mortality 2)Changes in the mean IMT of common carotid arteries 3)Changes in the pulse wave velocity (PWV) (rt & 1t baPWV), ABI [ Time Frame: five years ] [ Designated as safety issue: Yes ]
Same as current
 
Nippon Ultra-Rapid Insulin and Diabetic Complication Evaluation-Study (NICE-Study)
To Investigate Whether the Postprandial Blood Sugar Level as Achieved Using Ultrarapid-Acting Type Insulin Could Prevent Great Vessel Disorder in Japanese Type 2 Diabetic Patients.

For the purpose of comparing efficacy of intensive therapy between 1) ultrarapid-acting type insulin (insulin aspart) and 2) conventional rapid-acting type insulin (R), a Multicenter Open Label Randomized Controlled Trial was planned in Japan using the occurrence of cardiovascular events in patients with diabetes, a high risk factor, as an index.

A survey shows that the most frequently observed direct cause of death in diabetic patients is cardiovascular disorder. However, investigations and surveys such as DCCT, UKPDS and KUMAMOTO-study, etc. clarified that strict control of blood sugar level prevented development and progress of diabetic microangiopathy, but could not show a significant effect on great vessel disorder. Recently, the DECODA-study, DECODE-study and Honolulu-study have demonstrated that postprandial high blood sugar is involved in great vessel disorder. Therefore, possible prevention of great vessel disorder in diabetic patients is suggested by improving the postprandial blood sugar level as achieved using ultrarapid-acting type insulin, which has become available recently. Even with results in Europe and the US obtained, the life-style and incidence of complications in Japanese people are different, and there are many points that remain uncertain with respect to the direct application of foreign results to Japanese people. Therefore, in Japan also, it is necessary to conduct a large-scale clinical study and to establish high-level evidence using mainly Japanese people through hospitals having many patients.

 
Observational
Cohort, Prospective
Diabetes Mellitus
 
  • Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
  • Intensified insulin therapy with human regular insulin
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
346
December 2007
 

Inclusion Criteria:

  • Subjects are patients satisfying the following conditions 1) - 3).

    1. Outpatients and inpatients aged 20 years or more but younger than 85 years. Men or women.
    2. Patients with type 2 diabetes based on the diagnostic standard of the Japanese Diabetes Society
    3. No specific restriction on the current treatment. Patients having switched treatment are also accepted.

Exclusion Criteria:

  1. Patients with type 1 diabetes
  2. Patients with a past history of cerebral angiopathy (cerebral hemorrhage, cerebral infarction, transient cerebral ischemic attack, subarachnoid hemorrhage, etc.) within 6 months before giving consent
  3. Patients with a past history of myocardial infarction within 6 months before giving consent
  4. Patients planning to receive PTCA or CABG, or who had PTCA or CABG within 6 months before giving consent
  5. Patients with coronary arteriopathy (angina pectoris, etc.) that requires treatment with β-blocker or calcium-antagonist
  6. Patients with atrial fibrillation or atrial flutter
  7. Patients with renal dysfunction (serum creatinine ≥ 3.0 mg/dL)
  8. Patients with liver dysfunction (AST, ALT ≥ 100 IU/L)
  9. Patients with a past history or suspected of having a malignant tumor within 5 years before giving consent
  10. Pregnant or possibly pregnant patients
  11. Other patients judged inappropriate for the study by the investigators (patients presenting difficulty in frequently receiving rapid-acting type insulin or ultrarapid-acting type insulin therapy, including patients' compliance with treatment)
Both
20 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00575172
Osaka Saiseikai Nakatsu Hospital, NICE-study EBM center
UMIN0949, UMIN00000949
Osaka Saiseikai Nakatsu Hospital
 
Study Chair: Hideshi Kuzuya, M.D.,Ph.D Higasiyama Takeda Hospital
Study Director: Makoto Otoshi, MD.,Ph.D. Ohtoshi Clinic
Principal Investigator: Haruo Nishimura, MD.,Ph.D. Osaka Saiseikai Nakatsu Hospital
Principal Investigator: Koji Maeda, MD. Maeda Clinic
Principal Investigator: Mitsuyo Shintani, MD.,Ph.D. Osaka Saiseikai Nakatsu Hospital
Osaka Saiseikai Nakatsu Hospital
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP